News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
GlaxoSmithKline in Potential $1.9 Billion Tax Battle with IRS
May 22, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- British-based drug company GlaxoSmithKline is battling the U.S. Internal Revenue Service over a potential $1.9 billion in back taxes, interest and penalties.
Twitter
LinkedIn
Facebook
Email
Print
Legal
MORE ON THIS TOPIC
Vaccines
Pfizer CEO Responds to Trump’s COVID Transparency Call Touting Vaccine Success
September 3, 2025
·
2 min read
·
Annalee Armstrong
CDC
RFK Jr. Blames US COVID Deaths on Chronic Disease, Announcing CDC Reorganization
September 3, 2025
·
2 min read
·
Dan Samorodnitsky
FDA
Offit Out at FDA Vaccine Advisory Committee After HHS Rebuff
September 2, 2025
·
3 min read
·
Heather McKenzie
Manufacturing
Trump’s Push To Shore Up Pharma Supply Chain With US API Welcomed but Questioned
September 2, 2025
·
4 min read
·
Nick Paul Taylor
